Sagimet Bio­sciences files again for an IPO af­ter re­leas­ing NASH da­ta

Two years af­ter fil­ing to go pub­lic and then back­ing out, Sagimet Bio­sciences has made plans to try again on an IPO.

The Cal­i­for­nia biotech filed its S-1 with fi­nan­cial reg­u­la­tors on Fri­day, the same day it re­leased in­ter­im Phase IIb da­ta on its po­ten­tial NASH treat­ment, called deni­fan­stat. In an in­ter­im analy­sis at week 26, Sagimet said 67% of pa­tients on its drug had liv­er fat re­duc­tions of at least 30%, com­pared to 18% in the place­bo group, com­ing in at a p-val­ue less than 0.001.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER